Validation of a Sars-Cov-2 Nucleocapside N-Protein Detection Test in Saliva
Annals of Medical and Health Sciences Research
; 11:376-380, 2021.
Article
in English
| Web of Science | ID: covidwho-1481542
ABSTRACT
An antigenic method for the quantification of SARS-CoV-2 nucleocapside protein (LUMIPULSE SARS-CoV-2 Ag- Fujirebio) both on naso-pharyngeal swab and on saliva has been evaluated on three groups of subjects:
sub-intensive care unit hospitalized patients (n=24), patients discharged from this unit (n=22), controls (n=74). The molecular RT-PCR technique was considered the reference method. The cut-off value of 1.04 pg/mL distinguishes sick (hospitalized) from healthy (controls) with sensibility=0.937 and specificity=0.959;area under the ROC curve (0.978);efficiency=0.90. On saliva the qualitative antigenic result (positive if >cut-off) agrees with the qualitative molecular one (k=0.84). Stratifying by groups, in the hospitalized group (with clear prevalence of positives) there is a concordance of the positives of 97%;in the two groups of patients discharged and controls (with clear prevalence of negatives) there is a concordance on the negatives of 91% and 96%, respectively. The qualitative antigenic result on saliva samples is concordant with the molecular qualitative one on the naso-pharyngeal swab (k=0.76).
Search on Google
Collection:
Databases of international organizations
Database:
Web of Science
Type of study:
Prognostic study
Language:
English
Journal:
Annals of Medical and Health Sciences Research
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS